Osteoporosis, a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, is a significant health concern globally. The complexities of its management are continually being unraveled, with modern strategies focusing on early detection, effective treatment, and prevention of further bone loss.
Early detection of osteoporosis is crucial. Modern diagnostic tools such as dual-energy x-ray absorptiometry (DXA) and the FRAX® tool have significantly improved the identification of patients at high risk of fracture. The FRAX® tool evaluates individual patient models that integrate the risks associated with clinical risk factors as well as bone mineral density (BMD) at the femoral neck.
Pharmacological therapy remains a mainstay in osteoporosis management. Bisphosphonates, denosumab, and teriparatide are commonly used. Newer agents like romosozumab, an anti-sclerostin monoclonal antibody, are showing promising results in increasing bone density and reducing fracture risk. Personalized treatment plans are essential, considering the patient's risk profile, drug efficacy, potential side effects, and patient preference.
Non-pharmacological interventions, including lifestyle modifications and fall prevention strategies, play a pivotal role. Adequate calcium and vitamin D intake, regular weight-bearing exercise, smoking cessation, and moderation of alcohol intake are recommended. Fall prevention strategies should be individualized, including balance training, home safety assessment, and, if necessary, use of assistive devices.
Modern osteoporosis management is a complex, multifaceted approach that requires early detection, risk assessment, pharmacological intervention, and lifestyle modifications. It is imperative for healthcare professionals to stay abreast of the latest advancements in this field to provide the best possible care to their patients. The future of osteoporosis management lies in further understanding the disease's pathophysiology, improving current treatment strategies, and developing new therapeutic options.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation